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Abstract
Background: Low haemoglobin concentration has been associated with adverse prognosis in patients with angina and
myocardial infarction (MI), but the strength and shape of the association and the presence of any threshold has not been
precisely evaluated.
Methods and findings: A retrospective cohort study was carried out using the UK General Practice Research Database.
20,131 people with a new diagnosis of stable angina and no previous acute coronary syndrome, and 14,171 people with first
MI who survived for at least 7 days were followed up for a mean of 3.2 years. Using semi-parametric Cox regression and
multiple adjustment, there was evidence of threshold haemoglobin values below which mortality increased in a graded
continuous fashion. For men with MI, the threshold value was 13.5 g/dl (95% confidence interval [CI] 13.2–13.9); the 29.5%
of patients with haemoglobin below this threshold had an associated hazard ratio for mortality of 2.00 (95% CI 1.76–2.29)
compared to those with haemoglobin values in the lowest risk range. Women tended to have lower threshold haemoglobin
values (e.g, for MI 12.8 g/dl; 95% CI 12.1–13.5) but the shape and strength of association did not differ between the genders,
nor between patients with angina and MI. We did a systematic review and meta-analysis that identified ten previously
published studies, reporting a total of only 1,127 endpoints, but none evaluated thresholds of risk.
Conclusions: There is an association between low haemoglobin concentration and increased mortality. A large proportion
of patients with coronary disease have haemoglobin concentrations below the thresholds of risk defined here. Intervention
trials would clarify whether increasing the haemoglobin concentration reduces mortality.
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Introduction
Haemoglobin is a potentially useful prognostic biomarker
among patients with stable coronary artery disease because of
the pathological role of myocardial hypoxia in subsequent acute
coronary events [1,2] and the existence of interventions to increase
haemoglobin concentration [3–5]. Measurement of haemoglobin
is nearly universal in such patients, further underscoring the
relevance of understanding its impact on prognosis. While
previous studies suggest that low haemoglobin is associated with
mortality in patients with coronary artery disease [6,7], they have
been limited in their ability to describe the shape of the
relationship, to assess gender differences, and to compare patients
with angina or prior myocardial infarction (MI). Furthermore
there are concerns that the prognostic biomarker literature may be
subject to reporting and other biases [8]. Thus several questions,
relevant to clinical practice and the design of future trials, remain
unanswered.
First, at what concentration of haemoglobin does risk increase;
is there a threshold or is it a continuous graded relationship? This
question is important in order to define optimal haemoglobin
levels. While some studies have reported a continuous relationship
between haemoglobin and prognosis among patients with
coronary disease, others have reported a J-shaped relationship
[6,9]. No previous study has sought to evaluate whether and where
there is a threshold. Second, how strong is the relationship in
population-based samples, when accounting for coexisting condi-
tions? This question is important in order to estimate excess
attributable risks from nonoptimal haemoglobin concentrations.
Third, how does the association between haemoglobin concen-
tration and mortality differ between women and men, in whom
haemoglobin homeostasis is known to differ? Fourth, do effects
differ between patients with a history of angina only, and those
with a history of MI? Many patients develop reduced left
ventricular function after MI [10] and might be more sensitive
to low haemoglobin concentration. Conversely, low haemoglobin
may unmask symptoms of angina and bring patients to medical
attention earlier, potentially reducing the apparent effect of low
haemoglobin on mortality.
We evaluated prior knowledge on this topic by means of a
systematic review and meta-analysis, and sought to extend this
knowledge and address the above questions by carrying out a
retrospective cohort study using the General Practice Research
Database (GPRD).
Methods
Ethics Statement
The GPRD Division of the Medicines and Healthcare products
Regulatory Agency has been granted Multi-Centre Research
Ethics committee approval for all observational studies using
GPRD data.
Study Populations
Over 95% of UK citizens are registered with a general
practitioner and receive primary health care free at the point of
use. The GPRD contains anonymised electronic clinical records of
over 4 million such patients with details of consultations,
diagnoses, referrals, prescriptions, and test results. Its use is
supported by numerous validation studies on a wide range of
diseases [11] and it has been shown to have accurate recording of
MI [12].
Among GPRD patients aged 35 to 90, we defined two study
populations on the basis of coded diagnoses between 2001–2006:
firstly, patients with new onset stable angina and no previous acute
coronary syndrome (ACS), and secondly, patients with a first MI.
The date of the earliest stable angina or MI diagnosis for each
patient was designated the ‘‘index date.’’ General practitioners
routinely code medical diagnoses using the ‘‘Read’’ clinical
terminology [13]; our codes are listed in Tables S1 (stable angina)
and S2 (MI).
For the stable angina population, we included patients with a
code for angioplasty or coronary artery bypass but not angina only
if they had evidence of previous angina symptoms (e.g., a code for
chest pain or a nitrate prescription; the date of the earliest such
entry was taken as the index date). We excluded patients with ACS
within 7 d after the index date because their initial presentation
may have been unstable rather than stable angina. Further details
are given in Text S1 (Additional Methods), Figure S1 (flowchart),
and Text S2 (STROBE checklist).
From both populations we excluded patients who died within
7 d of the index date, patients with other cardiac conditions prior
to the index date (myocarditis, endocarditis, pericarditis, valve
disease, or congenital cardiac abnormalities), and patients who
were pregnant less than 3 mo before the index date.
Risk Factors and Blood Parameters
We extracted all values of routinely recorded blood parameters
(total cholesterol, haemoglobin, mean corpuscular volume
[MCV], creatinine) for each patient, along with information on
established cardiovascular risk factors (smoking, systolic blood
pressure [BP], diabetes, and family history). For continuous
variables, if values were recorded before and after the index date,
we calculated a weighted average by linear interpolation to
estimate the value at the index date. If only a single value was
recorded, or all values were either before or after the index date,
we used the single value nearest the index date.
Recording rates for established cardiovascular risk factors are
high because they are included in the National Health Service
(NHS) Quality and Outcomes Framework, which includes
incentive payments for high quality management of chronic
conditions [14]. GPRD smoking data has been validated against a
population survey [15].
We estimated the glomerular filtration rate (eGFR) from serum
creatinine using the four-variable Modification of Diet in Renal
Disease (MDRD) formula, one of the methods recommended by
international guidelines [16].
Comorbidity
Our adjusted analyses incorporated the Charlson comorbidity
index, a numerical score based on 19 groups of medical
conditions, which correlates well with mortality [17]. We regarded
a comorbidity as being present if a Read code for the condition
occurred prior to the index date (within the previous 5 y for
cancers). The Charlson index incorporates the following cardio-
vascular comorbidities: congestive cardiac failure, MI, stroke, and
peripheral vascular disease. The ‘‘MI’’ criterion was ignored for
the purposes of this study, as patients in the stable angina cohort
would not have had a previous MI, and patients in the MI cohort
would all have an index MI. We dealt with age as a separate
variable and not as part of the Charlson index, to ensure
consistency across analyses with different levels of adjustment.
Follow-up and Endpoints
We limited follow-up to the time when the patient was
registered and data from the practice fulfilled GPRD standards
of data completeness. We excluded patients who were not
registered with the practice for a minimum of 3 mo before and
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3 mo after the index date (unless they died within that time). The
primary endpoint was death from any cause, identified by a Read
code denoting death or transfer out reason of ‘‘Death.’’ We
investigated nonfatal strokes and ACS as secondary endpoints
(‘‘nonfatal’’ was defined as survival for more than 7 d after the
event). We chose to investigate these diagnoses as secondary
endpoints because they cause significant morbidity and share
many common risk factors with angina and MI.
Statistical Analysis
Our statistical model aimed to identify upper and lower
thresholds of an optimal haemoglobin range beyond which
mortality risk increased (Figure 1A, Haemoglobin threshold
model). Similar types of models have been used in other studies
exploring prognosis and biomarkers (e.g., glycated haemoglobin,
Selvin et al. [18]). In Text S1 and Figure S3, our model is reported
fully, following recent recommendations [19].
In order to minimise bias arising from variable selection on
statistical grounds [20], we decided a priori to include in our
model only variables known to be relevant based on previous
literature. We included age, systolic BP, total cholesterol, eGFR,
and the Charlson comorbidity index as continuous variables with a
log-linear risk profile; and smoking, gender, diabetes, and family
history of coronary disease as binary variables. We used a semi-
parametric Cox model with proportional hazards for all variables
except haemoglobin, and tested the proportional hazards
assumption by examining Schoenfeld residuals [21]. We analysed
stable angina and MI patients separately, with no risk coefficients
shared between the two analyses.
We also report hazard ratios (HRs) from a stratified model,
similar to the approach of Sabatine et al. [6], in order to verify that
our model was not distorted by any assumptions of its shape. For
each gender, we stratified patients into groups at 1 g/dl intervals
of haemoglobin, and used the interval with most people as the
reference interval. We performed analyses using R Version 2.9.2
[22], Matlab (The Mathworks), and custom software in C++
(source code in Texts S4 and S5).
Systematic Review and Meta-analysis
We searched MEDLINE and EMBASE for prospective studies
in which blood biomarkers were measured in patients with stable
angina or at least 2 wk post ACS, and a relative risk for mortality
or coronary events by haemoglobin concentration was reported
with a p-value or confidence interval (CI). Our search results
included studies focusing on biomarkers other than haemoglobin,
but that reported a relative risk for haemoglobin in the results. Our
search strategy, including a complete list of keywords, has been
published as part of a systematic review of biomarkers in patients
awaiting coronary revascularisation [23] and is also described in
Text S1 (Additional Methods) and Figure S4 (MOOSE flow
diagram). We excluded studies with less than 1 y of follow-up, but
did not exclude studies based on methodological standards, sample
size, or language. Two reviewers independently abstracted data
from eligible articles, with disagreements resolved by consensus, or
rarely by adjudication by a third reviewer.
We used the outcome of all-cause mortality, if available, for the
meta-analysis. Since no studies evaluated thresholds, the only
summary relative risk that could be obtained was linear. We
converted the HR for each study to the equivalent risk for 1 g/dl
lower haemoglobin, and calculated a summary relative risk using
the random-effects method of DerSimonion and Laird [24],
implemented in the ‘‘rmeta’’ package for R [25]. We weighted
studies inversely by the log standard error of the relative risk. For
studies which used an anaemia cutoff [26,27], we divided the log
relative risk by the difference in mean haemoglobin between the
two groups. For the study by Reinecke et al., which used quintiles
[9], we derived a linear relative risk by linear regression of the
quintile-specific HRs on mean haemoglobin per quintile. We
evaluated a similar model for our own cohort, with haemoglobin
as a continuous linear variable, for comparison with the results of
the meta-analysis. See Text S1 (Additional Methods) and Text S3
(MOOSE checklist) for more details.
Results
Baseline Characteristics
The number of eligible stable angina patients was 25,824 and
the number of MI patients was 19,443. Women were more likely
than men to have haemoglobin measured (88.3% versus 83.5%,
p,0.001), but there was only a slight difference in the percentage
of patients with any missing covariate data (23.0% for women and
25.1% for men, p,0.001). After excluding these patients, the final
number of patients analysed was 20,131 for the stable angina
population and 14,171 for MI. Of these, 861 patients developed
MI after initially presenting with stable angina and were included
in both cohorts, but with different index dates. The mean haemo-
globin concentration was 13.0 g/dl in women and 14.2 g/dl in
men (p,0.001).
Table 1 summarises the baseline characteristics for the angina
patients (Table S3 for MI patients). Patients with lower
haemoglobin tended to be older (p,0.001 for linear trend) and
were more likely to have diabetes (p,0.001), renal impairment
(p,0.001), and cancer (p,0.001). They also had lower MCV
(p,0.001) and were more likely to be taking iron supplements
(p,0.001) and nitrates (p,0.001). Among patients with MI and
women with stable angina, those with higher haemoglobin were
more likely to smoke (p,0.001), but there was no significant
relationship for men with stable angina.
Of the patients who were taking iron supplements, 47.8% had a
laboratory record of iron status, 11.7% had microcytic red blood
cells (MCV,80 fl), and 22.9% were iron deficient (ferritin
,25 mg/l, transferrin saturation ,16% or soluble transferrin
receptor .2.5 mg/l).
Absolute Risks and Kaplan-Meier Curves
In patients with stable angina and haemoglobin less than 11 g/dl,
the age adjusted mortality rate was 5.3% per year for women,
compared to 9.8% for men. However for patients with stable angina
and haemoglobin over 15 g/dl, the corresponding rates were 2.7%
for women and 2.0% for men. The adjusted Kaplan-Meier curves
show that lower haemoglobin was associated with a greater risk of
death in both genders over 4 y of follow-up (Figures 2 and S2).
Thresholds, Shape, and Strength of Association
There was a dose-dependent increase in mortality with
decreasing haemoglobin below the optimal haemoglobin range
in both genders and both study populations. For stable angina
patients, the lower threshold was 11.9 g/dl (95% CI 11.5–13.5) for
women and 13.1 (95% CI 13.0–13.4) for men. For the MI
population the lower threshold was 12.8 (95% CI 12.1–13.5) for
women and 13.5 (95% CI 13.2–13.9) for men (Table 2). Of men
with MI, 29.5% had haemoglobin below the lower threshold and
these patients had an adjusted HR for mortality of 2.00 (95% CI
1.76–2.29) compared to those with haemoglobin concentration in
the lowest risk range. Mortality was higher at both extremes of
haemoglobin concentration compared to the central range
(Figure 1B), but there were very few patients with haemoglobin
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above the upper threshold, so there is less evidence for a dose-
dependent effect at high haemoglobin levels.
These findings were corroborated by the stratified haemoglobin
model. For stable angina patients, the adjusted HR of death for
women with haemoglobin 11–12 g/dl (compared to the reference
group with haemoglobin 13–14) was 1.69; 95% CI 1.30–2.20
(Figure 1B). For men with Hb 12–13 g/dl (compared to 13–14)
the HR was 1.74 (95% CI 1.39–2.17). Among MI patients, the
corresponding HRs were 1.80 (95% CI 1.43–2.26) for women and
1.95 (95% CI 1.61–2.37) for men (Figure 1B; Table S4).
We defined the population attributable risk for low (or high)
haemoglobin as the amount that the total modelled mortality risk
for the entire cohort would change if all patients were assumed to
have an optimal haemoglobin concentration. Among stable angina
patients, the population risk attributable to low haemoglobin was
16% (95% CI 10–23%) for women and 24% (95% CI 19–29%) for
men. For MI patients the corresponding risk was 28% (95% CI 20–
37%) for women and 31% (95% CI 25–37%) for men (Table 2).
The excess risk attributable to low haemoglobin was greater for MI
patients compared to stable angina (ratio 1.44, 95% CI 1.10–1.88).
Figure 1. Adjusted HRs for death for patients with stable angina or MI, by haemoglobin concentration. (A) Legend and diagram for
haemoglobin threshold model; (B) HRs for death by gender and coronary diagnosis (new onset stable angina or first MI), adjusted for age, eGFR,
systolic BP, total cholesterol, family history, diabetes, smoking, and comorbidity (Charlson index). The black squares denote HRs from the stratified
haemoglobin model (with 95% CIs).
doi:10.1371/journal.pmed.1000439.g001
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After standardising for differing baseline haemoglobin between
the genders, the shape of the haemoglobin-prognosis relationship
was similar in men and women.
Subgroup Analysis, Secondary Endpoints, and Mean
Corpuscular Volume
In Table S5 we show that men and women in the highest
MCV quintile (MCV greater than 95 fl) had a slightly increased
risk of death compared to the middle quintile (HR 1.40 for
women and 1.49 for men with stable angina; similar results for
MI). Most of these patients had MCV values in the upper part of
the ‘‘normal’’ range, as only 3.1% of stable angina patients and
3.5% of MI patients had red blood cells whose size exceeded the
conventional threshold for macrocytosis (MCV.100 fl). Less
than 1% of patients in the cohort had both macrocytosis and
anaemia.
Subgroup analysis showed a similar association of low
haemoglobin with mortality among patients with and without
other comorbidities (Tables S6 and S7). There was no
significant association between haemoglobin and risk of stroke.
A post hoc analysis that included white cell count, congestive
cardiac failure, and high density lipoprotein (HDL) cholesterol
as additional independent variables yielded similar results to the
main analysis.
Systematic Review and Meta-analysis
We identified ten eligible studies [7,9,26–33] that reported the
relationship between haemoglobin and outcomes (1,127 events)
in patients with stable coronary disease (Figure 3). None of these
studies investigated evidence for the existence, or position, of any
threshold haemoglobin value. According to a linear haemoglobin
risk profile (a misleading model of the data), the summary
relative risk from the meta-analysis was 1.29 (95% CI 1.20–1.38)
for 1 g/dl lower haemoglobin. For comparison, the HR of death
for 1 g/dl lower haemoglobin in our study was 1.18 (95% CI
1.14–1.21) for angina patients and 1.15 (95% CI 1.13–1.18) for
MI patients.
Although the Egger test for publication bias was nonsignificant
(p = 0.38) [34], there was significant heterogeneity between the
studies (Cochran’s Q=17.96, p = 0.036).
Table 1. Baseline characteristics of patients with new onset stable angina, by gender and haemoglobin category.
Characteristics Women Men
Haemoglobin in g/dl $14.0 13.0–
13.9
12.0–
12.9
11.0–
11.9
,11.0 Missing $15.0 14.0–
14.9
13.0–
13.9
12.0–
12.9
,12.0 Missing
Number of patients 2468 3291 2332 854 499 2481 3853 3256 1987 886 705 3212
Mean age (y) 66.6 66.9 68.6 70.7 70.6 69.3 61.7 64.6 67.7 70.6 70.3 64.4
Age-adjusted covariate means
MCV (fl) 91.6 90.8 89.9 88.1 84.5 90.8 91.6 91.3 90.8 89.3 88.2 92.0
Systolic BP (mmHg) 143.7 142.4 142.4 144.2 145.8 142.5 141.8 141.2 140.7 141.1 140.4 140.8
Total cholesterol (mmol/l) 5.6 5.5 5.4 5.4 5.2 5.5 5.1 5.1 5.0 4.8 4.7 5.0
eGFR MDRD (ml/min) 66.2 66.5 64.4 63.3 59.9 64.2 71.3 71.8 70.7 68.7 64.0 70.1
Age-adjusted percentages
Current or ex-smoker 50.2 42.6 39.8 41.4 35.1 36.8 60.0 60.3 60.5 60.2 59.7 47.1
Diabetes 13.0 12.9 16.3 24.3 34.1 8.7 13.9 16.2 20.8 28.8 31.3 11.1
Family history of coronary disease 31.8 31.2 32.0 33.7 27.9 24.1 23.3 23.7 23.3 18.0 20.6 17.6
Other comorbidities prior
to index date (%)
Congestive cardiac failure 4.6 4.0 6.1 6.7 10.0 8.2 2.8 2.8 6.0 6.8 12.6 5.1
Peripheral vascular disease 4.5 4.0 4.4 6.4 7.4 4.9 4.6 6.0 7.2 9.8 12.6 6.0
Stroke 7.4 6.8 8.5 11.5 11.2 9.2 7.2 7.6 8.8 11.0 12.9 6.9
Chronic respiratory disease 26.2 25.2 23.6 26.5 27.3 22.4 19.3 20.6 21.2 22.7 22.7 18.0
Peptic ulcer disease 4.4 4.6 4.3 4.6 4.8 4.1 5.9 6.0 7.0 9.6 8.9 6.2
Cancer 1.3 1.9 1.7 2.1 1.8 2.3 1.1 2.2 3.3 5.5 7.9 3.4
Medication use in year after
diagnosis (%)
Nitrate 63.5 64.9 66.6 70.5 66.1 64.8 62.7 64.9 65.9 69.8 67.4 62.6
Aspirin 73.1 74.3 74.0 75.1 72.1 67.0 77.8 80.2 82.3 80.9 77.7 72.2
NSAIDs 24.3 24.8 28.7 28.7 28.9 22.1 19.4 21.7 23.5 25.1 20.7 17.2
Iron 1.7 4.2 6.4 20.0 34.3 6.5 1.2 2.5 6.2 12.2 28.4 3.5
Folic acid 1.5 1.9 2.1 4.0 6.6 2.6 0.6 1.0 1.9 2.1 5.8 1.7
Vitamin B12 1.7 1.6 2.1 3.3 5.2 2.0 0.6 0.9 2.0 4.0 5.2 1.6
Recombinant human erythropoietin 0.0 0.0 0.1 0.1 1.2 0.2 0.0 0.0 0.2 0.6 1.8 0.2
MDRD, Modification of Diet in Renal Disease; NSAID, nonsteroidal anti-inflammatory.
doi:10.1371/journal.pmed.1000439.t001
Haemoglobin and Stable Coronary Disease
PLoS Medicine | www.plosmedicine.org 5 May 2011 | Volume 8 | Issue 5 | e1000439
Discussion
Summary of Main Findings
The new cohorts of patients with stable coronary disease
reported here are substantially larger (3,174 deaths) than the
combined previous literature (1,127 events), allowing reliable
estimation for the first time of thresholds of haemoglobin concen-
tration for excess risk. Our study demonstrates that thresholds exist
(i.e., the risk is not linear, as has been presented in seven previous
studies). Furthermore, the thresholds are higher than clinicians
Figure 2. Kaplan-Meier curves for patients with stable angina. Unadjusted and multiply adjusted Kaplan-Meier curves showing the
probability of death in men and women with new onset stable angina according to haemoglobin level. Adjustment was done by stratification on
linear predictors from a Cox model, which included age, eGFR, systolic BP, total cholesterol, family history, diabetes, smoking, and comorbidity
(Charlson index), but not sex or haemoglobin.
doi:10.1371/journal.pmed.1000439.g002
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Table 2. Upper and lower threshold haemoglobin concentrations (with 95% CIs), and excess population risk of mortality
attributable to low or high haemoglobin levels.
Haemoglobin Thresholds Stable Angina Population MI Population
Women Men Women Men
Lower threshold
Haemoglobin level (g/dl) 11.9 (11.5–13.5) 13.1 (13.0–13.4) 12.8 (12.1–13.5) 13.5 (13.2–13.9)
Haemoglobin below lower threshold:
Percentage of patients 13.5 (8.8–56.1) 16.8 (15.6–21.5) 42.2 (25.5–62.8) 29.5 (23.8–36.0)
Relative risk of death 1.92 (1.44–2.38) 2.03 (1.72–2.40) 1.77 (1.51–2.10) 2.00 (1.76–2.29)
Population attributable mortality risk (%) 15.6 (10.2–22.7) 24.0 (18.5–29.4) 27.8 (19.5–37.4) 30.9 (25.0–36.5)
Upper threshold
Haemoglobin level (g/dl) 16.3 (14.0–17.5) 17.2 (13.6–18.0) 15.1 (13.9–16.6) 16.4 (15.1–17.8)
Haemoglobin above upper threshold:
Percentage of patients 0.5 (0.1–24.8) 1.3 (0.3–74.2) 4.7 (0.4–24.2) 5.6 (0.4–30.2)
Relative risk of death 2.65 (1.06–10.8) 1.11 (1.00–3.86) 1.81 (1.13–3.53) 1.14 (1.01–1.51)
Population attributable mortality risk (%) 1.3 (0.1–6.7) 0.4 (0.0–2.7) 2.5 (0.2–5.9) 1.7 (0.2–3.9)
doi:10.1371/journal.pmed.1000439.t002
Figure 3. Systematic review and meta-analysis. Systematic review and meta-analysis of studies investigating the relationship between
haemoglobin concentration and prognosis in patients with stable coronary disease. Legend: aCI not reported in paper; standard error estimated from
p-value. bReported by quintiles with fourth quintile as reference group; linear conversion by linear interpolation of relative risks across quintiles.
cCardiovascular deaths and ACSs (all-cause mortality not reported in this study). dDerived from anaemia cutoff; HR 5.73 (95% CI 1.49–22.1) for
anaemia (n=14, mean haemoglobin = 11.0) versus nonanaemia (n=129, mean haemoglobin = 14.4). eDerived from anaemia cutoff; HR 6.46 (95% CI
1.73–24.2) for anaemia (n= 71, mean haemoglobin = 11.2) versus nonanaemia (n= 239, mean haemoglobin = 14.0). fWe did not calculate risks from a
linear model because it over-simplifies the shape of the relationship. gTotal number of patients is less than the sum of the individual cohort sizes
because 861 patients were included in both angina and MI cohorts.
doi:10.1371/journal.pmed.1000439.g003
Haemoglobin and Stable Coronary Disease
PLoS Medicine | www.plosmedicine.org 7 May 2011 | Volume 8 | Issue 5 | e1000439
might anticipate, and thus a substantial proportion of patients
(15%–30%) have a haemoglobin level that places them at
markedly higher risk of death compared to patients with lowest
risk haemoglobin levels. Our findings were consistent in women
and men, among patients with angina alone, and those with a
history of MI. Our results also suggest that the risk attributable to
low haemoglobin was greater in patients with previous MI
compared to those with stable angina, and the optimal (lowest
risk) range of haemoglobin was narrower for patients with MI.
Based on our attributable risk calculation, the association between
haemoglobin and mortality might contribute to about a quarter of
deaths after MI.
Our lower haemoglobin thresholds accord closely with the World
Health Organisation (WHO) anaemia thresholds of 12 g/dl for
women and 13 g/dl for men; this is noteworthy for two reasons.
First, the WHO thresholds were defined to facilitate the detection of
nutritional iron deficiency, and were not derived in relation to
prognostic studies in any population [35,36]. Second, prognostic
associations often do not correlate with biomarker thresholds used
to define other conditions. In the case of diabetes, there is increased
risk with mildly elevated blood sugar levels that do not fulfil the
criteria for diabetes [37], whereas for chronic kidney disease, risk
increases only with moderate to severe renal impairment [38].
Like previous studies [6,39,40] we did find some evidence that a
high haemoglobin is also associated with poor prognosis, giving a
J-shaped relationship. However, there were few patients with high
haemoglobin and they contributed little to the overall population
risk (Table 2).
Gender Difference
The shape of the haemoglobin-prognosis relationship was
similar in men and women, after adjusting for the higher baseline
haemoglobin in men. Men have a physiologically higher
haemoglobin concentration than women, because of an erythro-
poietin-independent effect of testosterone in stimulating erythro-
cyte production [41]. Anti-androgenic treatments can cause
anaemia [42] and testosterone treatment can increase haemoglo-
bin [43]. However, it is unclear why women tolerate a low
haemoglobin better than men.
Stable Angina and Myocardial Infarction Compared
According to our model, the excess risk associated with low
haemoglobin was greater for patients with MI than for those with
stable angina (Table 2). If there is a causal relationship between low
haemoglobin and worse prognosis, a possible mechanism is that the
reduction in tissue oxygen delivery may lead to a persistent increase
in cardiac output and left ventricular hypertrophy, further
exacerbating myocardial ischaemia [44]. It is possible that these
consequences are worse in patients who have already suffered a MI.
Limitations
Our prognostic cohort analysis has strengths compared to
previous studies—size and statistical power, longitudinal recording
of comorbidities, more complete adjustment for a priori confound-
ers, direct derivation of clinical thresholds, and population base—
but important limitations. First, and most important, as our study
was observational we cannot conclude a causal relationship
between haemoglobin concentration and mortality. It is possible
that there was residual confounding, and the effect on mortality was
due to the cause of the haemoglobin concentration, rather than the
haemoglobin concentration itself. Our model included the
Charlson comorbidity index to encode the presence of heart failure
and other common chronic diseases, but it did not take into account
the severity of the coronary artery disease or other medical
conditions. Patients with more severe coronary disease or
comorbidities may have lower haemoglobin, as is the case with
chronic heart failure [45]. Hypoxia due to heart failure causes
vasoconstriction of the afferent arterioles of the kidney, with
consequent reduction in renal perfusion, activation of the renin–
angiotensin–aldosterone system and production of antidiuretic
hormone, causing plasma volume expansion and haemodilution.
Erythropoietin secretion is reduced because of renal hypoxia,
causing a further reduction in haemoglobin concentration, which
exacerbates cardiac failure [46,47]. This vicious circle of anaemia,
heart failure, and chronic kidney disease has been called the ‘‘cardio
renal anemia syndrome’’ [48]. However, significant confounding
from comorbidity in our study is unlikely because we obtained
similar results from the subset of patients without comorbidities,
and from those who survived at least 1 y after the index date.
Second, bias might arise because of missing data and variable
time intervals between measurement and disease onset. However
in about half of patients we used an interpolated haemoglobin
value (using at least one value before and one after the index date)
and found similar results to the entire cohort.
Third, information on cause of death was not available. However,
previous studies have shown that coronary disease is the most
common cause of death among the patients studied [33], so any
effect observed on mortality is likely to be due to coronary death.
Fourth, although the electronic recording of coronary disease
diagnoses in primary care is reasonably accurate and complete
[12,49], the diagnosis of angina is less reliable than that of MI, and
we were unable to further characterise either diagnosis in terms of
angiographic results, electrocardiographic findings, or markers of
myocardial necrosis.
Fifth, a shortcoming of our statistical model is that we only
included variables considered to be relevant on the basis of prior
knowledge. We did not consider interaction terms or nonlinear
effects except for haemoglobin, with the result that our model may
have been incompletely adjusted and may have missed some effect-
modifying relationships. However, we did specifically investigate the
most important interaction (haemoglobin and gender), and our
approach had the advantage of being less susceptible to bias than
variable selection and elimination on purely statistical grounds [20].
Sixth, we did not classify the cause of anaemia in all patients in
our cohort, nor did we collect data on blood transfusions. Blood
transfusions are recorded incompletely in the GPRD because they
always occur in hospital but are rarely the primary reason for
admission. However, we feel that these omissions would not have
influenced or main results, because the majority of anaemic
patients in our study had a haemoglobin level that was only slightly
lower than the average, and may not have been ‘‘diagnosed’’ as
anaemic in the sense that clinicians may not have considered the
haemoglobin level as unremarkable.
Contribution of Systematic Review and Meta-analysis
The systematic review clarifies the limitations of previous studies;
none had previously estimated the haemoglobin threshold values, or
had assessed men and women, or angina and MI separately. There
was significant heterogeneity between the studies, because they
included populations with differing baseline risks and were analysed
with varying levels of adjustment for other risk factors. In order to
combine the relative risks we had to assume a log-linear relationship
between haemoglobin and prognosis, and assume a normal
distribution for haemoglobin levels in the population. Given the
relatively small number of studies in the meta-analysis, it was not
worthwhile to attempt a subgroup analysis or meta-regression.
As a crude summary measure of effect, ignoring the thresholds,
the summary result from the meta-analysis (HR 1.52 per standard
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deviation [SD] haemoglobin) was somewhat larger than that from
our cohort analysis (1.31). This finding likely reflects our more
extensive adjustment for potential confounders. However, the
relationship between haemoglobin and mortality that we observed
was strong, comparable to that for low density lipoprotein
cholesterol (1.38 per SD) [50] and fibrinogen (1.24 per SD) [23].
Clinical and Research Implications
Our findings provide observational evidence that contributes to
the rationale for randomised controlled trials to evaluate
management strategies aimed at increasing haemoglobin among
suitable patients with stable coronary disease. Such experimental
evidence would address whether clinicians should intervene, and
whether haemoglobin levels are causal. These studies may include
a trial of oral iron supplementation, or a more aggressive approach
involving intravenous iron and erythropoiesis-stimulating agents.
Outcome measures may include clinical events such as mortality
and MI, as well as quality of life measures. We are not aware of
any such trials that have been reported or are currently registered.
Clinical practice guidelines for the management of angina state
that anaemia should be corrected [51], but do not specify
investigations, interventions, or the target haemoglobin concentra-
tion. 94% of our patients had normocytic red blood cells (MCV 80–
100 fl), and the extent to which causes of anaemia in such patients
should be investigated is not known. Although our study shows that
mild anaemia is associated with increased mortality, randomised
trials using erythropoietin in other conditions have shown that
complete correction of anaemia is not beneficial. In trials among
patients with chronic kidney disease, a target haemoglobin above
13 g/dl has been associated with higher mortality (Correction of
Hemoglobin and Outcomes in Renal Insufficiency [CHOIR]) [5]
and a higher rate of stroke [52] than treatment to a lower
haemoglobin target, and an increased risk of stroke compared to
placebo (Trial to Reduce Cardiovascular Events With Aranesp
Therapy [TREAT]) [4]. We found no relationship between
haemoglobin and nonfatal stroke, but the overall number of
strokes was small. In congestive cardiac failure, a meta-analysis of
seven randomised controlled trials showed a reduction in
hospitalisation with treatment of anaemia (relative risk 0.59, 95%
CI 0.41–0.86), but no significant effect on mortality [3]. The
ongoing phase III placebo-controlled trial of darbopoeitin alfa in
congestive cardiac failure (Reduction of Events with Darbepoetin
alfa in Heart Failure [RED-HF]) is aiming for a target haemoglobin
of 13 g/dl and is due to complete in 2012 [53].
Irrespective of a possible causal, reversible relationship between
haemoglobin concentration and mortality, further research is
warranted to assess what incremental prognostic value haemoglobin
might offer in risk stratifying patients with stable coronary disease.
Conclusions
There are threshold levels of haemoglobin below which women
and men with stable coronary disease are at increased risk of
death. However our study is observational and cannot be used to
infer a causal relationship. Outcome trials of strategies to increase
haemoglobin levels would be able to answer the question as to
whether increasing haemoglobin among such patients is beneficial.
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Editors’ Summary
Background. Coronary artery disease is the main cause of
death in high-income countries and the second most
common cause of death in middle- and low-income
countries, accounting for 16.3%, 13.9%, and 9.4% of all
deaths, respectively, in 2004. Many risks factors, such as high
blood pressure and high blood cholesterol level, are known
to be associated with coronary artery disease, and
prevention and treatment of such factors remains one of
the key strategies in the management of coronary artery
disease. Recent studies have suggested that low hemoglobin
may be associated with mortality in patients with coronary
artery disease. Therefore, using blood hemoglobin level as a
prognostic biomarker for patients with stable coronary artery
disease may be of potential benefit especially as measure-
ment of hemoglobin is almost universal in such patients and
there are available interventions that effectively increase
hemoglobin concentration.
Why was This Study Done? Much more needs to be
understood about the relationship between low hemoglobin
and coronary artery disease before hemoglobin levels can
potentially be used as a clinical prognostic biomarker.
Previous studies have been limited in their ability to
describe the shape of this relationship—which means that
it is uncertain whether there is a ‘‘best’’ hemoglobin
threshold or a continuous graded relationship from ‘‘good’’
to ‘‘bad’’—to assess gender differences, and to compare
patients with angina or who have experienced previous
myocardial infarction. In order to inform these knowledge
gaps, the researchers conducted a retrospective analysis of
patients from a prospective observational cohort as well as a
systematic review and meta-analysis (statistical analysis) of
previous studies.
What Did the Researchers Do and Find? The researchers
conducted a systematic review and meta-analysis of previous
studies and found ten relevant studies, but none evaluated
thresholds of risk, only linear relationships.
The researchers carried out a new study using the UK’s
General Practice Research Database—a national research
tool that uses anonymized electronic clinical records of a
representative sample of the UK population, with details of
consultations, diagnoses, referrals, prescriptions, and test
results—as the basis for their analysis. They identified and
collected information from two cohorts of patients: those
with new onset stable angina and no previous acute
coronary syndrome; and those with a first myocardial
infarction (heart attack). For these patients, the researchers
also looked at all values of routinely recorded blood
parameters (including hemoglobin) and information on
established cardiovascular risk factors, such as smoking.
The researchers followed up patients using death of any
cause as a primary endpoint and put this data into a
statistical model to identify upper and lower thresholds of an
optimal hemoglobin range beyond which mortality risk
increased.
The researchers found that there was a threshold hemoglo-
bin value below which mortality continuously increased in a
graded manner. For men with myocardial infarction, the
threshold value was 13.5 g/dl: 29.5% of patients had
hemoglobin below this threshold and had a hazard ratio
for mortality of 2.00 compared to those with hemoglobin
values in the lowest risk range. Women had a lower
threshold hemoglobin value than men: 12.8 g/dl for women
with myocardial infarction, but the shape and strength of
association did not differ between the genders, or between
patients with angina and myocardial infarction.
What Do These Findings Mean? These findings suggest
that there are thresholds of hemoglobin that are associated
with increased risk of mortality in patients with angina or
myocardial infarction. A substantial proportion of patients
(15%–30%) have a hemoglobin level that places them at
markedly higher risk of death compared to patients with
lowest risk hemoglobin levels and importantly, these
thresholds are higher than clinicians might anticipate—and
are remarkably similar to World Health Organization anemia
thresholds of 12 g/dl for women and 13 g/dl for men.
Despite the limitations of these observational findings,
this study supports the rationale for conducting future
randomized controlled trials to assess whether hemoglobin
levels are causal and whether clinicians should intervene to
increase hemoglobin levels, for example by oral iron
supplementation.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000439.
N Wikipedia provides information about hemoglobin (note
that Wikipedia is a free online encyclopedia that anyone
can edit; available in several languages)
N The World Health Organization provides an overview of
the global prevalence of coronary artery disease, a
factsheet on the top ten causes of death, as well as
information on anemia
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